Pharming Group N.V. Q3 2025 Financial Summary
Business Context and Reporting Period
This Form 6-K filing, dated November 6, 2025, presents the preliminary unaudited financial results for Pharming Group N.V. for the third quarter and nine months ended September 30, 2025. Pharming is a global biopharmaceutical company focused on rare diseases, primarily commercializing RUCONEST® (for hereditary angioedema) and Joenja® (leniolisib, for APDS). The company recently announced a strategic withdrawal from non-U.S. markets for RUCONEST® to reallocate resources to pipeline growth.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $97.3 million | $74.8 million | $269.6 million | $204.5 million |
| Operating Profit | $15.8 million | $4.1 million | $19.6 million | ($15.3 million) |
| Net Profit (Loss) | $7.5 million | ($1.1 million) | ($2.8 million) | ($14.7 million) |
| Cash Flow from Operations | $32.0 million | $9.7 million | $44.0 million | ($11.1 million) |
| Cash & Equivalents | $168.9 million | $130.8 million (Q2) | $168.9 million | $169.4 million (Year End) |
| Gross Margin | 92.7% | 90.9% | 90.9% | 88.7% |
Revenue Breakdown (Q3 2025): RUCONEST® generated $82.2 million (29% YoY growth), while Joenja® generated $15.1 million (35% YoY growth). The U.S. market accounted for 97% of total revenue.
Material Changes vs. Prior Period
- Profitability Surge: Operating profit increased 285% year-over-year in Q3, driven by significant revenue growth outpacing operating expense increases. The company returned to profitability for the quarter after a net loss in Q3 2024.
- Product Growth: RUCONEST® unit sales volume in the U.S. increased 24% in Q3 despite the July launch of a new oral competitor. Joenja® saw a 25% increase in U.S. patients on paid therapy.
- Strategic Shift: Pharming withdrew RUCONEST® from non-U.S. markets, which contributed only 1.3% of RUCONEST® revenue, to focus on high-growth pipeline opportunities.
- Restructuring: The company implemented a 20% net reduction in non-commercial and non-medical headcount to reduce G&A expenses by approximately $10 million annually. One-time restructuring costs of ~$7 million are expected in Q4 2025.
Guidance, Outlook, and Risks
- 2025 Guidance Raised: Full-year revenue guidance increased to $365–$375 million (previously $335–$350 million), representing 23–26% growth. Operating expenses are projected between $304–$308 million (excluding Q4 restructuring costs).
- Regulatory Catalysts: The FDA granted Priority Review for the pediatric sNDA for leniolisib (ages 4–11), with a decision expected by January 31, 2026. A commercial launch for this group is planned for Q1 2026 if approved.
- Pipeline Progress: Continued advancement of leniolisib for broader primary immunodeficiency populations and the FALCON study for KL1333 in mitochondrial disease.
- Leadership Changes: Leverne Marsh appointed Chief Commercial Officer effective January 1, 2026, succeeding Stephen Toor. Kenneth Lynard joined as CFO in October 2025.
- Risks: Potential impact of U.S. tariffs (management does not expect material impact), execution risks regarding the pediatric label expansion, and the one-time costs associated with the organizational restructuring.
Investor Verification Checklist
- Verify the sustainability of RUCONEST® growth in the U.S. following the July 2025 launch of a new oral on-demand competitor.
- Confirm the timeline and probability of FDA approval for the pediatric leniolisib sNDA (PDUFA date: Jan 31, 2026).
- Monitor the impact of the 20% G&A headcount reduction on operational efficiency and the timing of the $7 million one-time restructuring charge in Q4.
- Assess the progress of VUS (Variant of Uncertain Significance) patient reclassification, which could expand the addressable market for Joenja®.
- Review the cash burn rate relative to the $168.9 million cash position, considering the $68 million investment in Abliva shares during the period.